Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Biotechnology investors wary of repeating recent history are negotiating tougher term sheets, but are investors' protections adequately balanced with managements' incentives?
The country aims to boost its high-tech sectors, but a more proactive role in project detection and seed funding is still needed for successful incubation.
Biomedical researchers and institutions looking to commercialize their inventions are faced with an array of policies and regulations for managing potential conflicts of interest.